Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan.

Ichiro NakashimaJin NakaharaHiroaki YokoteYasuhiro ManabeKazumi OkamuraKou HasegawaKazuo Fujihara

Published in: Therapeutic advances in neurological disorders (2023)

This article reports interim PMS data for Japanese patients and provides updated real-world evidence for the safety of eculizumab and its effectiveness at preventing relapses in patients with AQP4+ NMOSD. Safety and effectiveness results are consistent with those from PREVENT.

Keyphrases

randomized controlled trial
systematic review
spectrum disorder
public health
emergency department
big data
machine learning
adverse drug